Skip to search formSkip to main contentSkip to account menu

meproscillarin

Known as: 3Beta-((6-Deoxy-4-O-Methyl-Alpha-L-Mannopyranosyl)Oxy)-14-Hydroxybufa-4,20,22-Trienolide, methylproscillaridin, proscillaridin 4'-methyl ether 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Cardiac glycosides are used clinically because of two important pharmacological properties, namely positive inotropism in the… 
1986
1986
The development of a sensitive and selective radioimmunoassay for determination of proscillaridin in plasma is described… 
1979
1979
Meproscillarin is a glycoside with a high bioavailability (about 70%) and an elimination independent of the renal function. It… 
1978
1978
It was to be investigated whether the elimination rate of 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa… 
1978
1978
26 patients with impaired renal function and 7 healthy subjects received an oral dose of 0.5 mg 14-Hydroxy-3-beta-[(4-O-methyl… 
1977
1977
SummaryIn a randomized, controlled, double-blind study 2 groups of 7 patients each with coronary heart disease received either 1… 
1975
1975
Summary0.5 mg3H-proscillaridin-4-methylether was administered orally to 5 healthy males. Maximum plasma levels of total… 
1974
1974
Das Herzglykosid Proscillaridin weist eine Abklingquote von 30% taglich auf. Bei Untersuchung der Plasmaspiegel dieses Glykosids… 
1974
1974
SummaryEight patients with renal insufficiency (creatinine clearance: 0 to 61.2 ml/min/1.73 m2) and six healthy subjects received… 
1974
1974
SummarySix healthy volunteers received 1.0 mg of methyl proscillaridin intravenously two times at a 21 day interval. During one…